Skip to content

Savara SVRA Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
TRV
Trevi Therapeutics, Inc.TRVI
Mannkind logo
MannkindMNKD
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's accrued liabilities, current?
Savara (SVRA) reported accrued liabilities, current of $11.04M in Q1 2026.
How has Savara's accrued liabilities, current changed year-over-year?
Savara's accrued liabilities, current increased by 74.2% year-over-year, from $6.34M to $11.04M.
What is the long-term trend for Savara's accrued liabilities, current?
Over 5 years (2020 to 2025), Savara's accrued liabilities, current has grown at a 21.3% compound annual growth rate (CAGR), from $5.58M to $14.64M.